iPSCs as a groundbreaking tool for the study of adverse drug reactions: A new avenue for personalized therapy
WIREs Mechanisms of Disease · 2024-01 · 16 (1)
DOI: 10.1002/wsbm.1630 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift WIREs Mechanisms of Disease, online erschienen am 28.09.2023. Verfasst von Paola Rispoli und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Surgery and Health Sciences, University of Trieste, Trieste, Italy. Hauptthemen laut MEDLINE: Induced Pluripotent Stem Cells. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 125 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Italian Ministry of Health, University of Trieste, Ministero della Salute.
Abstract (Originalsprache)
Induced pluripotent stem cells (iPSCs), obtained by reprogramming different somatic cell types, represent a promising tool for the study of drug toxicities, especially in the context of personalized medicine. Indeed, these cells retain the same genetic heritage of the donor, allowing the development of personalized models. In addition, they represent a useful tool for the study of adverse drug reactions (ADRs) in special populations, such as pediatric patients, which are often poorly represented in clinical trials due to ethical issues. Particularly, iPSCs can be differentiated into any tissue of the human body, following several protocols which use different stimuli to induce specific differentiation processes. Differentiated cells also maintain the genetic heritage of the donor, and therefore are suitable for personalized pharmacological studies; moreover, iPSC‐derived differentiated cells are a valuable tool for the investigation of the mechanisms underlying the physiological differentiation processes. iPSCs‐derived organoids represent another important tool for the study of ADRs. Precisely, organoids are in vitro 3D models which better represent the native organ, both from a structural and a functional point of view. Moreover, in the same way as iPSC‐derived 2D models, iPSC‐derived organoids are appropriate personalized models since they retain the genetic heritage of the donor. In comparison to other in vitro models, iPSC‐derived organoids present advantages in terms of versatility, patient‐specificity, and ethical issues. This review aims to provide an updated report of the employment of iPSCs, and 2D and 3D models derived from these, for the study of ADRs. This article is categorized under: Cancer > Stem Cells and Development
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Medicine, Surgery and Health Sciences, University of Trieste, Trieste, Italy.
- Institute for Maternal and Child Health IRCCS Burlo Garofolo, Trieste, Italy.
- Department of Life Sciences, University of Trieste, Trieste, Italy.
ORCID-Profile: Paola Rispoli, Tatiana Scandiuzzi Piovesan, Giuliana Decorti, Gabriele Stocco, Marianna Lucafò
Förderung
- Italian Ministry of Health
- University of Trieste
- Ministero della Salute
Zitieren
APA
Rispoli, P., Scandiuzzi Piovesan, T., Decorti, G., Stocco, G., & Lucafò, M. (2024). iPSCs as a groundbreaking tool for the study of adverse drug reactions: A new avenue for personalized therapy. WIREs Mechanisms of Disease, 16(1). https://doi.org/10.1002/wsbm.1630
Vancouver
Rispoli P, Scandiuzzi Piovesan T, Decorti G, Stocco G, Lucafò M. iPSCs as a groundbreaking tool for the study of adverse drug reactions: A new avenue for personalized therapy. WIREs Mechanisms of Disease. 2024;16(1). doi:10.1002/wsbm.1630
BibTeX
@article{Rispoli2024,
author = {Rispoli, Paola and Scandiuzzi Piovesan, Tatiana and Decorti, Giuliana and Stocco, Gabriele and Lucafò, Marianna},
title = {iPSCs as a groundbreaking tool for the study of adverse drug reactions: A new avenue for personalized therapy},
journal = {WIREs Mechanisms of Disease},
year = {2024},
volume = {16},
number = {1},
doi = {10.1002/wsbm.1630}
}
EUVIMED